Haldol-Depot (Haloperidol Decanoate)

Haldol-Depot is indicated for the treatment of schizophrenia and related psychotic disorders, particularly when long‑term maintenance therapy is required.

• Acute management of severe psychotic episodes requiring rapid symptom control.
• Maintenance therapy to prevent relapse in chronic schizophrenia.
• Adjunctive treatment for patients who have responded to oral haloperidol.
• Situations where adherence to daily oral medication is challenging.
• Use in combination with other antipsychotics when clinically justified.

Side effects of Haldol-Depot vary in frequency and severity. Patients should be monitored regularly for both common and serious reactions.

Common

• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Drowsiness or sedation, especially after injection.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or changes in appetite.
• Elevated prolactin levels leading to menstrual changes.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening condition.
• Tardive dyskinesia with persistent involuntary movements.
• Severe hypotension or cardiac arrhythmias.
• Hyperglycemia or new‑onset diabetes mellitus.
• Significant liver enzyme elevations.
• Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Haldol-Depot, clinicians should evaluate patient history and monitor for potential risks.

• Assess for cardiovascular disease, as haloperidol may affect heart rhythm.
• Screen for a history of seizures or neurologic disorders.
• Monitor for signs of metabolic disturbances, including glucose and lipid changes.
• Use caution in patients with hepatic or renal impairment.
• Evaluate prolactin‑related effects, especially in women of childbearing age.
• Discuss pregnancy and lactation considerations, as safety data are limited.
• Ensure regular follow‑up to detect early signs of tardive dyskinesia.

Haldol-Depot can interact with several medication classes, influencing efficacy or safety.

Avoid

• Other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk.
• Medications that prolong QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole) that could raise haloperidol levels.

Use with caution

• CNS depressants, including benzodiazepines and opioids, for additive sedation.
• Anticholinergic agents, which may mask extrapyramidal symptoms.
• Drugs affecting glucose metabolism, such as insulin or oral hypoglycemics.
• Medications that alter hepatic enzyme activity, like rifampin, which may reduce efficacy.